PENK Methylation Test for Detecting Bladder Cancer

Inclusion Criteria: * Individuals who agree to voluntarily sign an informed consent prior to the initiation of screening * Adults aged ≥40 * Subjects who have had gross or microscopic hematuria within the 3 months * Subjects who had no history of bladder cancer and upper tract urothelial cancer * Subjects who will undergo cystoscopy, NMP22 test, and urine cytology within 1 month after consent Exclusion Criteria: * Individuals who do not agree to voluntarily sign an informed consent prior to the initiation of screening * Subjects aged \<40 years * Subjects with a history of bladder cancer and upper tract urothelial cancer * Female who are currently menstruating or who have had their last menstrual period within the last 3 days * Subjects who have undergone invasive procedures in the urinary tract system within the last 3 months * Subjects with suspected upper urothelial cancer lesions on ultrasound or CT scan * Subjects who have previously received pelvic radiation therapy * Subjects who have been diagnosed with other cancers and have received or are currently receiving chemotherapy or immunotherapy within 6 months * Subjects who require treatment for an active urinary tract infection or vaginitis * Subjects undergoing prostate cancer treatment or requiring a prostate biopsy * Subject has any condition which, in the opinion of the investigator should preclude participation in the study